<SUBMISSION>
<ACCESSION-NUMBER>0001193125-06-150088
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20060720
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20060720
<DATE-OF-FILING-DATE-CHANGE>20060720
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>AtriCure, Inc.
<CIK>0001323885
<ASSIGNED-SIC>3841
<IRS-NUMBER>341940305
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-51470
<FILM-NUMBER>06971687
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6033 SCHUMACHER PARK DRIVE
<CITY>WEST CHESTER
<STATE>OH
<ZIP>45069
<PHONE>513-755-4107
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6033 SCHUMACHER PARK DRIVE
<CITY>WEST CHESTER
<STATE>OH
<ZIP>45069
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML><HEAD>
<TITLE>Current Report</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left"> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR WIDTH="17%" SIZE="1" NOSHADE
COLOR="#000000"> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR WIDTH="17%" SIZE="1" NOSHADE
COLOR="#000000"> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Date of Report (Date of earliest event reported): July&nbsp;20, 2006 </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>AtriCure, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of registrant as specified in charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR
WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-51470</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>34-1940305</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>6033 Schumacher Park Drive</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>West Chester, OH</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>45069</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (513)&nbsp;755-4100 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former name or
former address, if changed since last report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR WIDTH="17%" SIZE="1" NOSHADE COLOR="#000000"> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"></FONT><FONT FACE="WINGDINGS" SIZE="2" COLOR="#000000">&#168;</FONT><FONT FACE="Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><HR SIZE="3" NOSHADE COLOR="#000000" ALIGN="left">

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">On July&nbsp;20, 2006, we issued a press release announcing that we have received FDA 510(k) clearance for our Isolator Transpolar Pen System for pacing, sensing, stimulating, and recording during the evaluation of
cardiac arrythmias in addition to its currently FDA-cleared use for the ablation of cardiac tissues. We also announced the release of our new Isolator Transpolar open clamp. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">A copy of the press release is being filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Exhibits. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-right:0px;margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release of AtriCure, Inc. dated as of July 20, 2006.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">ATRICURE, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Thomas J. Etergino</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Thomas J. Etergino</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Vice President and Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dated: July&nbsp;20, 2006 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT LIST </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-right:0px;margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release of AtriCure, Inc. dated as of July 20, 2006.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px">

<IMG SRC="g61022img.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Contacts: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="72%"></TD></TR>
<TR>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>AtriCure</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Thomas Etergino</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Chief Financial Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">513-755-4561</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">tetergino@atricure.com</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>The Ruth Group</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Stephanie Carrington /
Nick Laudico (investors)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(646) 536-7017 / 7030</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">scarrington@theruthgroup.com</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">nlaudico@theruthgroup.com</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Jason Rando (media)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">(646) 536-7025</FONT></P> <P
STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">jrando@theruthgroup.com</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Press Release </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>AtriCure Receives FDA 510(k) Clearance for Multifunctional </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Isolator&#153; Transpolar &#153; Pen
System and Releases New Isolator Transpolar </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Open Clamp </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>WEST CHESTER, Ohio, July&nbsp;20, 2006 </B>&#151; AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that it has
received Food and Drug Administration (FDA) 510(k) clearance for its Isolator Transpolar Pen System (Pen) for pacing, sensing, stimulating, and recording during the evaluation of cardiac arrhythmias in addition to its currently FDA-cleared use for
the ablation of cardiac tissues. The AtriCure Pen is the only bipolar radiofrequency (RF) device that is cleared for this broad range of indications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The
new capabilities of this multifunctional Pen allow physicians to identify potential trigger areas on the heart that could cause cardiac arrhythmias. Additionally, physicians may ablate these targeted cardiac triggers and directly evaluate the
effectiveness of the ablation, all with the same device. The multifunctional system includes specialized electrophysiology accessories that enable physicians to toggle between each function. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Separately, the Company announced the release of its new Isolator Transpolar open clamp, which leverages the design enhancements of the Isolator minimally invasive
system released during the first quarter of 2006. This new open clamp features a design that improves the surgeon&#146;s access to key anatomical structures, simplifies the ablation procedure and provides superior tactile feedback to the user. The
clamp currently has clearance from the FDA for the ablation of soft tissues in general, thoracic and other non-cardiac related surgical procedures. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Building on the foundation of success in more than 25,000 cases worldwide, the new open clamp utilizes AtriCure&#146;s proprietary, automated ablation algorithm and further reinforces AtriCure&#146;s market leadership position in surgical
ablation devices. These devices deliver energy tailored to the biophysics of the tissue being ablated and are currently being evaluated in ongoing FDA clinical trials for the treatment of atrial fibrillation. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The first case with the new Isolator Transpolar System was conducted on June&nbsp;28, 2006 by Patrick M. McCarthy, M.D.,
Chief, Division of Cardiothoracic Surgery at Northwestern Memorial Hospital in Chicago, IL. &#147;My experiences with the new Isolator open clamp have been very encouraging. The new design makes the system easier to position around structures and
the ablation lines are much more visible which assists in completing a successful ablation procedure,&#148; said Dr.&nbsp;McCarthy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dave Drachman,
President and CEO, said, &#147;The clearance of our multifunctional Pen and the release of our new open clamp represents our commitment to superior clinical outcomes through innovation. We believe the expanded indications for the Pen will drive
adoption in both the open and minimally invasive markets, while the benefits of the new open clamp will further strengthen our market position. These innovative products represent important steps in our mission to improve human life through the
treatment of patients who suffer from AF.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2"><U>About AtriCure, Inc. </U></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft and
cardiac tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably
create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a rapid, irregular quivering of the upper chambers of the heart. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities,
events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by AtriCure of new products and market acceptance of
AtriCure&#146;s products. Forward-looking statements are based on AtriCure&#146;s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are
subject to numerous risks and uncertainties, many of which are beyond AtriCure&#146;s control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure&#146;s products, AtriCure&#146;s ability to develop and market
new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure&#146;s products, competition from
existing and new products and procedures or AtriCure&#146;s ability to effectively react to other risks and uncertainties described from time to time in AtriCure&#146;s SEC filings, such as fluctuation of quarterly financial results, reliance on
third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected.
AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g61022img.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g61022img.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4P$#`P$1``(1`0,1`?_$`-L``0`"`@(#`0$`````
M```````("0<*!08!`P0""P$!``$%`0$!``````````````(!`P8'"`D$!1``
M``4#`P(#`P8&"PD1`````0(#!`4`!@<1$@@A"3$3%$%1(F%Q@3(5"O!")#46
M%Y%B<B,S0U6U=C<XL<'14E2T-G<HX:*R4V1TA)1%==4F)Y<86!D1``$#`@0$
M`P0&`PL)"0````$``@,1!!(%!@<A,4$342((83(4%7&!H4)2%I%B([%RLM(S
M4S1TE!<W\$-C<[-4-648P=&"DJ(D)455_]H`#`,!``(1`Q$`/P#?XHB41*(N
MA9.R)!8IL6XK^N,531=O,3NCMVX%%T^7$0(V8M2G$`,NZ7,!0]P"(^`54"IH
MJ$T%5B3CER=M3D7'SBD1#R%M35OK(A(04FY;O%_1.0_)I!NZ;$32604.`E,&
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M&,8=`*4H!J(CX41:Z66YN3Y)\GWS.(446+<EXM;-MP2EW"W@XYR=D5SY?PDW
M)-$EEAZZ&$OCUKZ`,+`5;)J5PG)#";SCQD].VF,F\DH\S&-N&VYUTV(U56,5
M0/-`4TC'(*L>_1ZZ"(=0JK/,*JA%#17S8`R,AE7$5D7F14%'C^';-I@N\#J)
M34>F5I(D6Z!M5462\T2^P%`JPX4*N`U"S)455*(E$2B)1$HB41=<NZ[;?L6W
M):[+IDD8F!A&IWDB^7W"1%(H@4I2D(!CJ*JJ&`A"%`3'.8`#J-5`)X!.2Q)B
M#DSB/.#^2B;$G7*TO%HBZ7BY6.=1+Y5B"H(^N:HNB%]0V`YR`82CN()P`0"J
MEI'T*@-5GZHJJ\:U2H181S)R4P+Q[CDI3-.5[+QTV<:@U)<<RV:O79@()RE:
MQQ3*/UQ.`:%VIB!AZ!619#I/4FIY3#D%E<73QSP-)`^EWNC]*Q34VN-(Z-A$
M^I\QM;)AY"1X#G?0T5<:]*#BJ_IGO@=N^&D31QLJ7+)F*?8+R%QU=\E'#\>S
M<5XC'>68@^.H?B]:V7!Z?-T)XQ*+.)@/1T\33^C$M.W/JLV6MIC"<PG>1U9;
M3.;]1P\?JJLWXS[I/`_*[YI%6UR'LUC+OUB(,8FZCO+5?.UCF$I4T$YMLT3.
M?4/#?KIU\*Q[-]G]QLEC=-=Y9.Z!HJYT=)`!XG`2LIR+?_:/4,K8+'.;9EP\
M@-;-BA+B>@[@`K[*J>[-ZSD6K=]'NFSYB[23<-'K-=)TT<H*AN37;N$#G161
M4*.H&*(@(>%:VD8^)YCE:6R--""*$'P(/(^PK<,4L<T;9H7-?$X5#FD$$'D0
M1P(/B%]514THB41*(E$2B)1$HB41*(E$2B)1$HBC3RXR43%^"KSF$E_)EIEF
M-K08`8"G/(SJ:K8PD\1`R+$%C@(!T,4/#QJ3!4^Q4)H%7)VX,8FN#(=P9*D$
M!7866P&-C5UB@=,]PS!0.JH`CK^_M6!=X#KJ'FC5V4T\H4&BI4H>XKB[]*<5
MQN0(]N*DKCZ0`[TR91%12W)+]X>^8<--J+)P)%QZ>P:A&ZAIT*DX<%B#MH9-
MV*7IB1^OT4TN^WB'.!2E,'EM)EJD3Q.JJ`IK#IIH5,:E**^8*C#T5M]65->!
M$``1]@!K]%$57+_FE=%^<B;)QA93-2V+0:WR$+/.W'IG,O<H-#KH+)#JF=*.
MC3J)B(%((JG#34Q?"KN`!I<5#$:T5HVOX?A\]6E->:(E$2B+"_('$YLUXIN7
M'J,F$.[E2L7,?(*%44;I/XQ\A(-2NTTQWG:+*H`0^@&$"FU`!$`J378755'"
MHHHA\1N&EY85OQ_?M\SL0JLA%.X>&BH-1=<%C/3I>>_?+JID(")42"5-(-3;
MA$3;=`UD]X(H%0-H:E61ZA5M25(_=C[I:7$"*#"N&CLY7D)=401ZYDEB%=Q^
M+H"0*H5I,.VIDUD7]RR!2B9FT/H4B8@NH`E%,IN@-E]GG:XF^?Y\',TQ#)0-
M'`W#V\V@\"V-OWG=3Y1UIRKZB?4`W;:#\JZ8PR:TN(P2X\6VK'<&O(H0Z5U/
M(T\`/.[[H,'>%_9RO#DP@QY-=P&][]EY*^$@GHC';F8<DNI]&2`@^CY&[9MP
M=PK!,G@+>8E$M4T]B1]#"B.A:V%K[?2PTFYVDMM;>V;';G"Z8-':#F^5S8V"
M@<12AD<34CABYK4^UWIFS/7<;-=[QW=Y)-=CN,MB\B9S7>9KYI#4QM-26Q-`
M(::'![JMV+VANW.5B#(>,=IF,#8&XOC3M["_,8$]GJ3+!<P$%R(_%KLV[O9I
MTK2/]]NZ/<[GS:8"M:8(J?13M\ETF/3ALOV>S\CA]VF+NW&+Z:]WG]7U*L#G
M'V&,9)X^NG(O$F0G;?NRVHN0FUL77"_/.0ETM622KMRPMZ4<>6]A),&R8@V2
M5\])8X:&.34!K;^WGJ/S8YE#E.M612V4LC6?$,`8^,DT!>T>5[:GS$82!QH5
MH/=;TB9"S)Y\]VY?-#F4#'2&UD=W&2AHJ6QO-',=0>4.+@3P);S5N_;)F#SG
M`GB^_4V@H7&K:.4(7=^]'A9>5AC(G*?XR*H"P$ARC]4Y1#V5I'=R`6VY.<1#
ME\67?3C:U]>'#CBJ/$+H[82Z=>;/:?F=3%\`&4'3MO>RGTC#0CQJ%.S7\/?\
MU:Z6W5YHB\:_[M$36B)K1$UJE>%434*KUHB:_A[OPTH@XIJ%$37Y!HB:_/3B
MB\T1*(E$5,/<IR;]JWI:^+F2^K2U(X9^:33/U^V)D@>C15(77=Y,:0BA->H&
M4'I5Z(<*E0<>BL`X@XO_`%6X,M.-<MP;S<^V+=,]N(!5@?S*9'!&ZIOQ_1M1
M(F7W`%6WFI]BD!0+/MV6Y'W?;$_:TJD1>/N"(?Q+M-0!,04GK=1`3"`::[!.
M!@^4*H#0U55KI6'+S'&WD7''?"NFO8MZ*P$X302*/H%5T#%[J!OJED(M8J@"
M(?"!M:^@@.;4<E:Y%;([5RW>MF[QHL1=J[02<METC;DUF[A,JJ*R9@Z&(HF8
M#`/M`:^975#/)&0>7\/?]PL<?8@MNY;";*MTX*2>RC9F_>I"P;&<K+":3`2@
M5\94"@*11V@`?+5P!A'$\5$DJG3'LO>+#D)#347;2$Q>Z-^.'J=JB_(S;NY@
M73DR\6$B8JI$2>88Y0..X`TUJ\X5:?!0ZJZIAE/E4N3S'G%V*0*<I3)%1S';
M!E=1UW`NDZ8M3I"'TC\E?/1OC]BN5/@NUY&RCE>R<8M[Y:8D8OIAG'/9.[K=
M>7Q&-T[;;M"`8/*DFC9ZG,JG`==J!0#0/'6@`)IT0DTJH'8T[AT[*W-<DWDI
M*'AK0B+9<.H2UH%J=25FYU14I&C$C]VH)W"I@ZZ@5(B9=1,`U<,8Z*(<>O)<
M7<W,'F))-U[MMC$JENV4=,ZS%=:S9B:0!`""L"KF854:)KZI%`?@23``$?'Q
MH&,Y'FJ%SNBE_=G)>_+`Q3;>2I?$;^XH1U:=MRTW<D;/0L;'HRDTW;%.D6%5
M<.IQJV(^7`IC'1$I0,&@FJ&`%U*J6(TJN@\4N4U\\A<KW>SF6,;;]K1-I>NB
M;?C]72B3L\LQ0]2^E%DDEGBX(J&*&TB28`;ZHCUJKF@-J.:`DE3;R%>L5C:P
MKVR'.B)82Q;4N&[Y?:8I3C'6W$NY=X5,QQ`H*'0:"!=>FHU]669?/FN8V^5V
MO])N9V1M_?2.#1]53Q7YV=9I;Y'D]WG5Y_1;.VDF?^]B87G[&K2%X%6A+=P?
MN:-+XRJJ:X6:]T7%G&]&ZY3&9NHRW)%!Q`P1$SG$C6,0DGK%--`-R?ITA2`N
MT>GH-N1?0[9;2.L,E_92"%EI$1S#I&D/?R!+BT/)=SJ:\UY2;09=<;S;\-S7
M4/[:,W$E].#6A;&X%C*5H&!QC;AY81AHMZ@B94R%33*1--,I2)ID*!2$(0`*
M0A"E``*4I0```.@5YUFKC4FI7K:`&@-:*-`7LHJKUJI$63415*!TU2'34(/4
M#D4*)3E$/<8HZ4!+2"W@0:_6J.:'`M=Q!"P)(VZYX[X/?0?'O%[:[5[3+,25
MKXZ4NIM;;5VO/7%(7).[KCG!<HL42OIATYT,!QT'RTR_5"LDBNF:GU"VXU1>
M.@;,6MDG$9D(#&!C/(RA/!C6]/$E8=/8OT3I-]IHK+VW+K;&Z*V[HB!,DKI9
M/VLE0T8GO=U_"!R"U]<+=Z'D+R>YB8*PO&V):F&;$G<AHPUYQ3%^I>ER2R;,
MCQ-U''N*0C8MJR8JKI_&5!F"H[0VJA[>F<_V$TSI#0V99]-<S7^91VI=$XCM
M,;7#0X`YQ+J<B74\6KC/2WJBUIKW<W*-+06EOE>42WHCG8UW>D?0.JWNN:P-
M;4<<+*^#O':)KD)=_*DON8=S#D)P6N",BXGCM:,I95]^N8XWRC/9%*NK*2T)
M&1CNXTG^/XB+4?,D8US+)%1,L^2]0GU`"CJ!=_[3;3:8W$MGS39I.S,+:AGM
MV04#6N<X,I.YU"7!IK1APGQ7*N^V^VL]I+ML%ODEM)E=V"VVNY+D'&YC6&3%
M;L;B:&%[0,3QB''AR$@^U'R2RKRNXM?K@S#*Q\I=TOD6^6&D3%MXB*CHN-E1
M0CXN/9H"8Y6K1'X2BJHJJ/XQQ&L8WETID^C=7_(\C8YEDRUB/F<7.<XMXN<3
MU/4``>`"S;T]:XU!N%H#\RZED;)F,M[./(T,:UK7#"QK1]UO(5)=XDK`_<X[
MAW*+A,U1>VEQ^LM>QKEE!MVS\L7+?2<L+F;3C_7KD=X[AVZ$@U;$3`P$.N]2
M!0Q=-`Z:Y)M'M?I#<!Y9>YG.,PA9CEMHX<-&5H*3N)!->8:PT6&[];TZ_P!J
MHQ+EV36IRF>3MPWDDX?5X;B.*V8`X"G(N>*T4%L"][B^X3C<ZD[ZCW'('EAD
M7)]TQ]B8SM>-0B(RVK::MXPL8I)-89FZ?MX@'"ZOI$0*Y>.C`;<H!"B<NQ-2
M>G[+KC538LN<W+-%VMI&9IY'%[I'DNQ4+R`74`Q'RM;T!)H=3:1]5F:VNB73
M9JQV<[B7M_(V"VB:&-BB#682X,:7!F(NP-`<]U#4T!(_.#^<G=BF.6.!&/(+
M&=XXYPYDK)]K6C+PZN%GMNVW]D7._)'(&2F99NYDT3)^:4WGBZTZ";3V4U!M
MYLQ!HS,Y--7<%UGMI:22-<+MKY,4;<1JUI#?9APII3=CU$W.XF3Q:RL;BQTS
M?7\,+V&Q=%'@E<&BCWMQ5%:XL?2JO"YM<XL1<',9#?&1'"DO<DR*[.P\>1:Z
M)+AO*41`@K`W\W<1A$1Y52F=/%0\M(!`H`90Y"&Y\V_V\SO</-QEV5@,M64,
MT[@2R)IK2M.;G4HUHXGGP`)75NZV[.FMILB^;9VXR7TM6V]LPCN3.'.E?=8V
MM7O/`<`*D@*C*Q^0_>>[B"3F]^/[2`X_87<OG:$-/(H0<4P>H(K"B=JA<-V,
MI.<NLS94#$5=1S-!(#IB4=/`>A\QTML/M>X9?J9TN99\&@N8<3B">-2R)S61
M@CDU[B>17)N4ZU]4&]3'9MHYL63:7+W!CP(V-<`:81+,U\DI!X%T3&MKP-.(
M7'Y(QCWV^*\7(Y/99F<YBM^&]1.7.QMIU`7D!&:2!7+U5S:TW`,9M>-;I("*
MOH"%%(I!,`E`1$;N4YQZ<]92MRB2P%C=249&9`^+B30`2,>6!Q)X8^!K16<\
MR'U;[>P/S^',WYG8Q5?*V-T<_E`JXF%\;9,(`->V/*!X<589VQ.['"\S%%,2
M99BXNQN0$2Q6>H(1IE$+;R!'L@(5\]@FSHYW$7+LC&U<,#G4T)\29S`!@+K'
M=S9>?0;1G>2O?<:9>_"2ZG<A<>37D<'-/1X`X\"!PKN?83U%6NYY.G-11QVF
ML8V5`;PBN&CWC&#4L>.9CJ>'%I/$"Z+4/?[-?H]]:$74:\T1<=+RC&#BI.:D
MUBMHV'CWDH_<'^J@R8-U';I8WR)((F-]%$6OCCJ,D>3O*U!_()'797!>+RZY
MDNOG),[8AW8NR-M1TU:"F1%L4.FA5=*^DT:SVJUS=[%<;R2Y6X&X@V*UO/-M
MYL[1B'2AXVW8E%!>0GKA>M4`4&.@(1D15X].@B`"H<"E11*("H<H"%9#I/1F
MHM;9@<NT];F:9H!>ZH:Q@)I5[S0"O0<ST!6&ZZW%TCMQE0S;5ETVW@>2V-H!
M=)*X"N&-C07.(ZGW6_>(47^,7=HX><J+U:XWLV[)JT[\E5U$+>MK(,0$`O<I
MT_JHPD@BZ?Q#EZN'5-J9P1TH`#M3'2LPU=LKKK1M@<UOX(YLN8`7OA=C$=?Q
MM(:X`=7!I:.I6O\`07J,VSW!S1N1Y9<2VV;R.(CBN6=LRD=(W`N87'HS$'GH
MU8![C^+@M_($#DJ/;"G&WLP&,EU"$VI%N")()DCF$.HN'T:(B(^Y&M5Q.!%/
M!;S?PY<U/3A)D_\`65@>W4W:_G3=E&-9\ON,`J')')D&*<B774J*D:H1,NNN
MXR)AJ$C<+J*;34*71_JF_<F_N5!56NYB;^V#`?ZV)#Z0]>]^:OH=[I"MMYK8
MEKYU<6(,^A_Z*Y._H?,?YL:JM%2`J'DJ->%-@1.0L^6E'3S1%]#PS20N1RT7
M*4Z+EQ%-@48(KHG_`(9$71@$0ZA\-?1(:-X<U!HJ5L3@0H%`@%*!0#:!`*&T
M"Z:;0*`````>ROF5Q12YK$(EQER.0A"$(5K#@!"%`I"A]O1O0I0T*'C[JFSW
ME%W)0&[9O]:-^?T')_/<?4Y/=5&\U-GN(ED3<'>4(1?FB['$-T"`(Z>8+8&Y
M1?Z:_B>@!3=^UUTK-MKNU_>'D_>IV_CH^?*M>'VT6L=Z^]_=/G_P]>[\MEY>
M%/-]6&M?95:UGW=PT<'*;*8+^5]HFPX<8_>`^;Y`7#&^N\KIIMZI;OHKK#U0
MB7\G61%>U\?YO"N!U/\`M7#/HK[(W"S$24[WRTX?&G<9BI]BW(JX37INE$2B
M+B9S\RS'_=<CI_U1:KUO_2(_W[?W0OGN_P"BRC_1N_@E:!W;S`?_`-*<(B("
M&F:I01$0'VNI4?=7I1N=_A3F'C\O;^XU>.>RW^.>5'_FKOW7K^@/7FBO91:R
M7WDO_0WB1XC_`.;,O^P1_P"Q;$]U=:^E,TO\ZK_,VW\*9<'^N,__`!6G?]?>
M?P;93#["0_[!$1T'^L[(OO\`Y9'W]:P;U(?XD25_W2'^"MF^D'_!^+^NW'\(
M+"/WBH?]FK#&FNGZVW&NFNN@6ZX]H>%9#Z6^.K,PK_N0_P!H%B/K7I^1<K/_
M`#$_[(K"_P!W5P9;"T%FSD%+13-]=2,S%8^M*1<H(+K0L6#->0N%1B*I3JLG
M<@L9!,RI-AC(`8@B)3"%?O>J/4-XVXR_3,+W-LRQTTC02`]U<+*T/%K?,0#7
MCQX$!8OZ*-)6!M,UUE<QM?F+9&6\3B`2QN$ODPUJ6EQP@D4JT$<B5L^&T'J;
M;H'4==-`Z:[M1\-*Y#Y?2N^>',\E_/\`>YSR,?<E.;V3IB9DGP6)8=V*XNM1
MFF)W*$3;-FR*D1+/6#8#$245FI9N[>B8`*90%2%$="%T]+]HM*QZ3V^M(+=K
M?F%S!\1*>1=)*W$P$^#&EK.M*$TXE>-F_>MY==;K7]U=/?\`*+.X-K$WF&Q0
M.+'N:*TJ]X?)7F:@=!38NL+O;]N['-DVG85K%R+#VY9]O1-NPT8SL%=-NS81
M3%%F@B0I'10,($2U,;Q,81,/41KEK,O3]NAFN839E>?"R74\KGO<9A4N<22>
M2[;R?U6;*9'E5MD^7?&Q6-M`R-C&V_!K6-``Y^SCXE=N#OU<#/#[1R?X#KK8
M;D>@_P#2QKX_^F_<@"N"TI_KA_W+]+_K`V@Y%]_3^KG^,M7/,F?\;VQSSE.2
MW&)>6A;%;92B<FV^@>,/`N&(N'B$A<\.E&I`/IF#C>Y1`@:@*:H^-=?Y%IK-
M;O;EFD]7AC\P=9N@><6,.H"V-V+J?=-?$+@/4NL<CL]WW:XT#W(LK&8MN8A@
M[9;5P=(P-Z-)+V_05O7?K^C/\@'^SO\`K^_COS9_D'U/'_?_`"5YU_EJ;\7_
M`-I\'T][Q_RX+UM_.5M^`_\`!/F/7W/P_3]JD16+K-5"+GQDO]!<&/H%FN*4
MSD1ZG;378?8NG%I@5[-N2!XF("!$VYP_Q7-3C!)KX*+CP6#NVIC'T5OW=E=\
M@)5IMT%K0!CD#I'Q9@5DW2)@'H#A^H"1@$/XCI4Y7`F@Y*C1U5%/WAI._`Y3
M8T5FBO!L0V*6Q+(-M.$<#LLN\&XR%,411&0]:("8!`%/*V^)=!KN;TPNRW\G
M7;+?#\R^,/='#%3".WSZ4KQ\:]5YE>M-N;_GZR?=8ODYR]O8/W:XW=T5Y5Q4
MKUIAZ45(>)"70?*N-$[(^T37<:_+2"VPBO."1^V/MUB+,6WIP\\#>9U';^)K
MKTUKH'.S9#)KLYAA^"^&D[F*E,.`UY\*47*&EQ?NU#8C*L?S(W4?;PUQ8\8P
MTIQK6B_H;<F\72>5>.LS"R*)'%YPT"QN9MZ9-,PJ7-",B.WS9L)=I$TY`Y54
M=2AIL/T"O)J0Q"Y?V*_#XW8:\\->'V47N];BX^$C%U3XKMMQTY8J#%3V5K15
MN]NO)PVIEI_8;YSY43D*,.FV3.;8F6XX@IG4><VHZ;W#05T"ETU%10*I(T%O
M#FKK>:O*/]0_[DWL^2K"N+7;Q.8`Y@P'^MB0#YOR][^S]%?0[W2K0/F`6Q-7
MSJZL0Y^_J6R;_0^8_P`V-4F>\%0\E45VWFR*N;Y)=0FY5M9;T4#;C!L%90B:
MGPAH4V\GOUTJ[)[J@WFKTZL*XHI\VO[,^2?^:P_\_1E39[RB[DH!]LW^M&_/
MZ#D_GN/J<GNJC>:N/N"(1GH*9A73.)D4):,?1ZC&=8$E85V5VV51!"7C#BF2
M0C5!.`+(B8/,3U+J&NM+69]M<QW#'/:YCPX.8["\4-:M=T<.AZ'BK%[;,O+.
M6UD;&]DD;FELC<<;J@BCV_>:>K>HJ%J:XC[K%\X$YBM<4YIXT<4<-0D-D20Q
M=DVZL88N=V5=L%%'DSQ@R"4XI<CAO]BHODFSIR*B1DCMB"<-!`HAVEG>S>7:
MDT*<YR'-LZO[F2U%Q;QW%P)8WNPXJ%G;!QD8FMH:AQ`\5YU:;]0N::.W-;IW
M4^1:>RNVBO'6MU+:VA@FC;BP%PD[I';#@U[JBA8*^"VVFCQJ_:MGS%PB[9O6
MZ+MFZ;J$6;NFKE,JS=P@JF)B*HK)'`Q3`(@8H@(5Q2]CXGNBD!;(TD$$<01P
M(/M"]'(I(YHVS1.#HGM#FN!J""*@@]01Q!7TU%37C6B+X)186\9(N"D34%!@
M\6!-4F]%04FZAP(J4!#>F<0T,'M"IPM#Y6M->+@/M_=5FX=@MY'T!+6$\>1H
M#S]BU+.('<MN_)W-7&&*'O%[AW:S*X,F/8!2[K-P\XA;XCDD5GY/M")G#7(Z
M*UE#BCU5%$0$1'IUKM;7.T]EE&@;S.&9SGL\L=H']N6Z#H7<O*YF`5;[,7UK
MSEVTWUS'/MT;#3TF0:9MXIK\QF:&R,<[15WF9)W2`_AQ.'ZEMQ:_ATKB;V+T
M@5%?>AYHO.*Z6!8F"Q)@G+DQ=:]\23YEG"Q#WRUM^,9(P;9D\MQ)*8BCQKF2
M=&63<F'>"A$4P#02C71&PN@F:P?F4]S>YE900B)H-I-V2]QQDA_E=B#10MY4
M)/BN2?5%NB[;]N46]MEN49E<W'?>6W]O\0(VM[36F(![,)<2X//&H:WP4H^T
M[GN3Y(<3H_)$OCW%V,G:U\WE$#:^(;74M"T$R1DD*!'B<.H_DC%?NP^)=3S1
MWFZZ!6'[SZ:@TKK-V4P7=Y>1BWB=W+F3NR^9M:8L+>`^Z*<`M@^GC5\^M]NV
M9Y<667V+W74K>U9P]F'RD>;!B?YB3YC7BL9=XSDY,<7<*XUNN'Q9AG*R\_D)
M:$5B,TV8I>L'')EAEG0/HMBG)Q8MI$1)L%03F^`1#2OV=BM(P:OU!=V<][?V
M38[7$'6LO:>[S@87.PNJWK2G-8]ZF]>W&@-*V.86V7Y7F+YKPL++Z#OQMI&7
M8FMQLH[I6O)<]V@N0<]R7XZW1D:;QEAC%8IY&EK?:P.%;/6LN$<EC&+)15_*
M1ZLC)@XD%#NP`%`/]0-!"ODWPTS;:3U3#E5M=W]Y_P"U:\ONY1*X8G$`-<&M
MHWARIS7W>FO65WKG14^=7-AE>7@7KHQ'8P&!APL:2Y[2Y]7>:E:\E:VL!O*5
M!,I3J>4IL(?J4QQ*.TI]1#4IC=!]X5IH>\*G@NAG5PF@!=1:7UV=U"YK2Y"7
M-8%_\/.$:4%;>7YFTKP>J8.5-<Y8J*N]Q$S;L[]:Y5T#S0M43G%8R)R"MJ82
M"`Z5WI9;.6E]IF',LLSW4!N);%LD8%V`S$Z(.8,.`$,J0*5'#@#5>768>H&]
MR[6<^39QIG2@MH,RDAF/P'[7"R8L>[$92.Y0$XBT@NXTHML.,XV<7Y6.CY1C
M@3"#IE),FK]HY;8ULA9NX;.T$W""Z"Q(<Q%454E`$I@$0,`ZA7&,VJ]7PRNB
MDS+,!(UQ!!GE!!!H:C%S7HE!H/;^X@9<19-E+HGM#@1:P$$.%00<%"".17V_
M_%SC3_\`7W"O_MA9?_@U6_SAJS_]._\`[1+_`!E=_N]T'R^2Y53^JP?Q%^1X
MM\:!U*;CYA00,`ZE'%]EB`@(:"`@,+IH(53\XZL''YGF']HE_CJIV^T(1_P7
M*O[+!_$67/T8MS^08;\Q?HQ^;&?^CG\@_P`%^9O^3?P/[6OQ?B[K^<D_E.Y[
MQ]_\?/W_`-;G[5DOP-C_`#,7\EVO=;_)?S?+W/U?=]BYVOG7U*B;GA?;[)N?
M&6/H`YG[:T"Q]J1K1$QCIN;JFETOM`$R@(_E0.G"30_0.J(!\M7V"C?:K;C4
M\%<AB&P6>,<:6=8[,"Z0,&Q:NE`+L%S(BB521='#KH=R].<P_/5EQJ25,<`N
MB\C.+6#N5UDA8.<['87C"-W!GL4X,JXCIN!?G3\LSZ"G8]5O)Q;@Y-`/Y2@$
M5*`%.4Q>E9)I76&HM&7YS+3MPZ"X<*.%`YCQX/8X%KA](J.A"PW6VW^D]Q,K
M&4:LM&7-JTU8:ELD;J4Q1R-(<TGK0T(X$$*-7&KM7<.>*]YIY%QW8+Z4OIGY
MP0]R7K./;G<P(+:`8\(T=B6.CWA2]`<E1]24!$`.`"-9;JS>/7>L<O\`E6:7
M+69<ZF)D3!&'T_&1YB/U:X?8L%T)Z>]LMO<T&=Y)9ODS=M<$L\CI3'7\#3Y6
MG]8-Q>U6*G3*H0R9RE.0Y3$.0X`8IB'#:<I@$-!`P#H.OC6K0MVK74S[:LIQ
M[Y*2;J%`[%*-N=C?MHK`02)@P=O0DD2I%(!2@BS>D6;E(`_52`/;7T-\S:!6
MSP*V!K,NB-OFT;=N^).!HZYH5A,-=#%.9(C]J18R"@D$2@NW.<4U`#P.40JP
M>!4QQ"U_X55MC7F(0]TK?9[*`S`\2?O%R^6F@V6EW""+Y03B4J;,Q7!5!/KH
M"8B;PJ^>+"1RHK=*.!\%?)=>6L;V3&(2UQWE`,6KPR*<>4LBV<NI-5R<B;=*
M-9ME%7#TRRBA0`2%$H;@$P@'6K`!/)7*A<#GA4JV$,DK$UV*V5*JEU#0=IV@
MG#4->@Z#56^\$/)5)]MLY0S5+$$Q0,>RW6PHF`!/M6()MH".IMH=1T\*NO\`
M=4&\U>=5A7%%'FV8I>,^21,(``MH8H"(Z=33\8``'O$1Z`'MJ;/>47<E`#MF
MKI!E:^T!.`+&L,52I]=QDTYV+*<X![BF5*'TU.3W51O-76U94UKQ]X[M;36?
M1><G^/L25_E6'B$F^0[`8H%!UD*(C4Q*VG((J90\^[8UKHFHB;J]0(&T05)H
MIT[L3O#;Z:#='ZF?AR:1]89B:B%SN;'_`.C<>(=]PGB"#PXM]3?I_NM8DZ^T
M;&'Z@BC`N+=HXW#6B@DCISF:.!:??:!3S"CJV^!G><R=Q(C6>"N1=HS^1,:6
MDJG`19RF"-R;C=NQ4!LM#F;RP))SL?&D3$J;)T=LNB;X2KE(&VMK[C[#Y1K>
M5VH=+31VN;S`O=]Z"<GCBJWW'.YE[<0(XEM>*T=M!ZH,_P!N(6:1UM;37N1V
MY[;/N75L&\"RCZ"1K*$"-Y:YO+&!P5]]J]Z3MU7)$HR;[.A[-75(F<T-==D7
MJ260%0@'$BQ;?@K@C]Z0CM-M<&#<'01#K7-M[L)NC:3=J/+A.SCYXY8L)_\`
M.]A_]*[!R[U0[*W]L+B7-76SR!Y);>XQCV'MQR-X=:.*C9G3OZ\8K007A<!V
MK>^>+W=J^A@@0C%;7M%=\N;R&AA=O2KW*_.9<Y1*V2CB*+!\(*$,(#65Z<]-
MFK;]PN-236^6Y>!5]7=R3".)X"D;>%?,7D#P(6#:M]86@\L8;71]O=YOFSCA
M9Y3#"2>`-75E=QI1HB!=RQ`J>'`*XN6&2,)SN0N7\4RM:\LCW7*3EHV*SCOL
MI2R,>.XYDVAH1Y&*D%XS<BL1=;8[57=[%"BJ<##L+KC<JUT7E6?QY9H=[IK&
MTA:R64G%W9@XE[@[D12@\H:VH.$4XG;NSUYN'G>EILZW(8V#,[ZX=)#`&X.Q
M;EC0QA9[P-<3@'ESZ$8S7@-/>[&#_@MW/EI"_6$BRA,8<C$;R5.U;G37D\;R
MET!--)6*(!DTG0/+4?`8"D.)/.`R0CJ!M.Y;*2+<3:/M9:]CI[O*NT*NX-G;
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ME&A\GDTK;31SYY"6R7CF<0)9!Y6>(#6@``BM.)%2O-G??6>?;D9]#KF\MY;7
M3-PU\.7LD]XPPNHY]!^-[B7$&F*K14-!6ROV&`8AV_[;,V=@N\/DK)AI)L'0
M6"H7&N1LB8!#Q6:%(KKJ/\)I[*Y.]1QE.Y<V-M&?"P83XC!Q/U&H^I=V^D9L
M(V<M^V^LGQEQB'X3CX#ZQ0_6L(_>)6P*\8L1.?4M4O29;$?3K+>6Z=>=`N4Q
M]&B)1\_R?K*=0VEZUD/I>?AU=>MH36RY]!YQS/2O(>U8AZUX\>@\M?B:,.8G
M@3Q-8B/*.M.O@NX?=[W+=3A==+<BR9UVV9KJ.X1*8HJHE7CH<414(`[B`J"9
MMNOCH-?#ZFV.&OH7D'"ZQCH?H<ZOZ*K];T:/8=KYV`C&W,I*CPK''3]-"KW:
MYRYA=<+3G[Y_!.?QKE]]RNL"!</,8Y45:FO\(MDHJA95_HMTFCB2D?3I;&41
M=B2*:Q5C:%]?YP&-N43`>ZO3QN+:YOD0T7F<H;F]F#V<1XRPDU`;7FZ(D@C\
M&&@HTKS*]6NT=[D.I7[BY-$79!F!'Q&!I/8N``TN=04:R8`$$\.YB!-7!90[
M;G>WMG$N.+9P+RL87"YA;/:(0=CY6@&Y9APUMUN!4HR#O"',L@Z.A"-`!%!Z
MU,JH9N0B9T3&**AOQMUO3]=YWFLVI-&.B;/.XOEMWG""\\7.B=0BKSQ<QU!B
MJ0X`T'[^QOJKL-.9';Z/W#9,ZVM6B."[C&,B,<&QS,J"0P<&O94X0`6DC$;K
MC]VWMV)Q(RX\G;1.W!+S00)!7R:0,/L2"._1;UOFB;IH)`^4=.M:!&RFZ)F[
M/RB?%7GCAP_I[E/M75/_`%&[*]CXCY];8:<NW<8_HP=K%7ZOL4)Y3O`R_)7/
MN,./7!"P+CN8LQ>\&;(N5;E@4P81=ALY$BER.(:&4%ZDP9K1R9@"2DA2VB<"
M$0!02FK8$&QUOI33=YJ?<>YBB,=N_L6T;_,Z8M_9AS^%2'?YME:TJ7$<%JN?
MU*W6NM7V&C=H[*><27<?Q-U+'Y6VX<.Z6,\V`8*_M9:4K0-Q4*OSKFU=@T73
M<B7BPQ[8UUWM)&*#2V8*1EC$,;;ZA5JW.9JT(/\`QKQUL2)^V.%5`J:!4/)4
ME\*K+?9BY'.+]GP.^;VPXD+\F7"Q1.1S/2+I<L.DMKKHJ9ZN=P4===6U7Y/*
MWVJ#>:OFKYU<2B)1$HBKMY^X`E\DVO$Y%M!BM)7%9"#IO*13-$57LK;C@Y5U
M5&J:9#*N744LGYA4PU$R1U-H";0!N,=0T47#JHR<-N8D?B]BGBW*"[E.T0=G
M&W;A!,50ME1RH91U'R2)0%P:,6<J"H4Q0,9$XF#:(#TD]E>7-4::*=.3N+^!
MN3"R5]MY0Q)1XB@FM==BRT>J$DDFDF"!7Z9DG\>LY21*4NXZ8+%*`%$>F@0#
MW-X*I:"NOV'P"PO9LXQGI-_=U\N8IR@\BVMTRC<\>S<ME"*HJ>CC6;%)P!%$
MP,!5-Q=0#ITJO<<F$+/N8<,LLR1"-O2]XWE;L`**B,C#VM(MXUI-)G,0Q22N
M]HNHY13V!M3U`GR5%KL*J151YMC@)C:RIEK<5HWWDZW9QF"A6TI$SC%H[3(L
M04U4P43C`$R2I.ABCJ`A4C(3T"IA"F_&,U8^.8L5GSJ359M4&RD@^%,SQX9%
M,$_4NC(II)F<*[=3F`H;C:C[:MJ2P%F?CE#YQ6*G=-]7\P@2HM4QM.$EVS.W
M%5VJIUB/G#!1DL#EZ)S!\9Q$2[0TTTJ378>2H158CM+@7CVPYI"XK-O_`"A;
M<TW`2)R$3.L6BYD#&*95JL9.,#SFJVW0Z9M2F#Q"I=P^`5,*G(F4Q"$*8YE#
M%(4IE#Z;CB4N@G-M`I0,<0U'0--:MJ2\Z#\G^"E`BA5R.[>7$?E2N:3RYB.%
M>7,8FP;SMLZ]IW<<I"&!$KJ=@CLW<@BB8VXJ;@54]?$!K/M*[GZWT<WLY+?/
M%H/\U)22+VT8^H%?%M"M6:WV7VWW"?\`$:DRV)U__/15AF-.59(\)<!X.J/8
MH$)?=^N$A)0[T\QF!9@;3;#FN]F5L300'H[3B"2)M0Z=51K9)]2^X'9[898B
M3\7;-?T8\/V+3S?1KM4+@RF7,S">4?>;A'UX,7Z2IV\>^W)PZXQO$9C%F&H%
M*YFYQ4;W?=1W%XW4T.8NAQ83-PJ/G,<!^@B"'EE`0Z`%:ZU/NGKK5T9M\XOY
M#9GG%'2*,_2UE`:?K56W-%[(;9:"E%UI_*X1?CE-+6:5O[U\F(M^AM%.#3\.
MM:]6V%$#E'P3XS\PV;$F;L?-IB;B4#-H>\8=VX@+OC&PF,H#1&>C3(NUX\%C
M"<6RPJ(";Q+6<:/W%U;H9[OR_<EEN\U=$\!\1/C@=P!_6%#[5K7<#:/0>YD3
M!JNR;+=1BC)F$QS-'X1(VA+:\<+JMKT4(K![$7!*RKH0N23A;[OQ)H\(\9V]
M=UUJ+V^4R6P2(/64<UCSRC3<74R3@ZA#ZZ&`0Z5L',_47N)F%H;6%]M;$MH7
MQ1T?](+B["?:`*=%JG)_2-M)E=\+VXBO+QC78FQ33$Q\.CFM#2]OL<2#UJ%(
M'EQVP^/7,%/&3.\W-TV1$8F@WENVC!8X6AH&':13M1%3TOH5HAZBFFW\@H)@
MD"8`'CK6,Z(W<U/H8W;[`0W$U[('ROGQO<7#K4.!XU-:U68[D;!Z+W+%A'F;
MKBTMLNA,4,=L8XV-82#3"6.``H*4HOCXA=LS''"R\U+GQ+F#-KB!?,9)M-XX
MN2XXA_8DX\?)()-YM[$MX1HHG,Q94/WA9)0@Z&$#;@Z5<USNUFNO\O%IG5CE
MXNFN:63L8\3,`K5@<7GR.KQ!'T*WMML1D>UN:G,-.9GFKK-['!]K)(QUN]S@
M`)',$;3C;3RN!'.AJ%PG*7M98UY@7@M=&9,W9\E(]"1<R%M62SNF'1LNS1=H
MHH+HVW#+0+@C0%4T0`RAC'5-J.IAJ_H[>'-M#6(L\BR_+62EH$DIC=W9:$D&
M1P>*\^7+V+Y-P?3[D6Y>9&_U/FV<R0AY='`V5@@AJ`"(XS&0.7$\2>I7T\6>
MU[CWA]<R4YAO.6?(R&<2C64N.Q'UT0KFR;N4:)*H(DGX5.`0(X,1!8Q"JD,1
M8@#\)@J.L=WLTUS:&WS[+LM?.&%L<PC<)8JFIP/QFG$#AR]BGM_L#DNVF8"\
MTQF^<QVKI`^6W=*PP3%H('<9VQ7@2*BCAXJSJM1K?:XF<@8:YHF0@;BBHZ=@
MY9JJRDXB79-Y"-?M%BB19L[9NDU6ZZ*A1T$IBB%7K>XN+2=MS:O?%<,(+7-)
M:X$=01Q'U+Y[NTM;^V?9WT;)K21I#F/:'-<#S!:000?:JB\L=C7@GDN;>S\1
M;%VXM>2+A5R[:8]N15E!^8J?>)64#*H2D7%HE\`3;)I)@'@76MW9+ZA]QLIM
MFVL\T%Y&T``SQXG\/%[2USOI<25S=J+TF;1Y[=.O+:WN<OE>XDBVEPLJ?PQO
M#V-'L:`/8L<P/W?CA+&2*+N6F\PW*S(.JL4^NYC'MW'4!^-S#0S!^3H&GP*E
M&OU+GU,:_FB+(([&*0_>$;G$?4Y[F_I"_#L_1KM7;SB2YES.XB'-CIFM!^MC
M&N_05:?Q_P"+6!N+ULFM7!^.("R&"^TTB]9H"YGIE4@`4JTU<#PR\M**@4``
M!65,`:=*TYJ?6&I-87?QNH+N2XE'N@FC&`]&,%&M^H+H/1NWVC]`6/R_2=C#
M:0GWG`5D>?%\CJO?_P"(E2`T_N:5C2S)8QS-C-IF'&EU8Y>R3B(1N1HW2+(M
M2E.JU<L7[239J"F80!5'U;(@*%U`3)B(`("-5!H:JA%118[XT\<H?CO:\I$M
MI4]P3D_(`^F9L[4C0%4VY!28L6R!3*&3:M2&,8`,8PBHH8?#0*JYV(U5`**2
M=14DHB41*(O&GTZZ]!\.M$41,N\*,+99>+S)XUS9EQN3F4<S-I>G9`\5.(F.
ML^C%$5(]TX,.@"H)`/H&FO6IB1P42T%1@0[=F0+:=G4L'/KJWVIMP`4T9*HK
M[##J(&",F6;41-[1!,*GW0>8JJ8/:NQQ_"KD`T6\Q?DZ^<%_Q!97%I[-?K7`
M;W57NM_"$PGQ63(KB]F%B!0<YV=.Q#3J+6:`1T_=3)J=UOX0F$^*R!'8*R,T
MV^?E=PXT\?R>2#=\^Z2-4,3?!5H?%=S9XLO)N!?-OU980TUU2>AKI\[P:IB9
MX*F%=D;6+<:.F^ZU%?9U3<^'TN1JF(>`5:'Q*YM"V)A+3=.F/\Y5_'Z5AJGB
MJT7)(PD@3Z\H8_0?8K[?G5&A-55?<6-<ETU>"(A\A_?\IZ#@J`4ZKZDVBQ?K
M+[OH-K_PJH>:4%:]5[RHJ%_C!_9-_AHJKV%(<!U$XB'NU'^^-$7MHB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
:1*(E$2B)1$HB41*(E$2B)1$HB41*(E$7_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
